A randomized, double blind placebo controlled phase III study of regorafenib plus best supportive care vs placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progre
|Effective start/end date||12/1/10 → 6/30/15|
- BAYER CORP
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.